{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 4/80', '4.6.2. Blinding and Unblinding', '40', '5. Investigational Medicinal Product', '41', '5.1. Identity of the Investigational Medicinal Product', '41', '5.2. Dosage and Administration', '41', '5.3. Packaging, Labeling, and Distribution', '41', '5.4. Storage', '42', '5.5. Treatment Compliance and Drug Accountability', '42', '6. Clinical Study Assessments', '42', '6.1. Timing of Assessments', '43', '6.2. Unscheduled Visits', '44', '6.3. Initial Subject and Disease Characteristics', '44', '6.4.', 'Subject Diary Card', '45', '6.5. Efficacy Assessments', '45', '6.5.1. Modified Rodnan Skin Score', '45', '6.6. Safety Assessments', '46', '6.6.1. Adverse Events', '46', '6.6.2. Clinical Laboratory Evaluations', '46', '6.6.3. Physical Examination', '47', '6.6.4. Vital Signs', '47', '6.6.5.12-lead Electrocardiogram', '47', '6.9. Other Assessments', '49', '6.10. Sample Management', '51', '6.11. Schedule of Activities', '52', '7. Statistical Methods', '55', '7.1. Determination of Sample Size', '55', '7.2. Population for Analyses', '55', '7.2.1. All Screened Subjects', '55', '7.2.2. All Enrolled Subjects', '55', '7.2.3. All Randomized Subjects', '55', '7.2.4. Full Analysis Set', '55', '7.2.5. Per-Protocol Set', '55', '7.2.6. Safety Analysis Set', '56', '7.3. Statistical Analyses', '56', '7.3.1. General Statistical Considerations', '56', '7.3.2. Primary Analysis', '56', '7.3.3. Interim Analysis', '56', '7.3.4. Analyses of Demographics and Baseline Characteristics', '56', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 5/80', '7.3.5. Analyses of Efficacy Parameters', '57', '7.3.5.1. Analysis for Primary Efficacy Endpoint', '57', '7.3.5.2. Analyses for Other Efficacy Endpoints', '57', '7.3.6. Analyses of Safety Data', '58', '7.3.6.1. Extent of Exposure', '58', '7.3.6.2. Adverse Events', '58', '7.3.6.3. Clinical Laboratory Evaluations', '58', '7.3.6.4. Physical Examinations', '58', '7.3.6.5. Vital Signs', '59', '7.3.6.6. 12-Lead Electrocardiogram', '59', '7.3.9. Analysis of Other Assessments', '59', '8. Data Monitoring', '60', '8.1. Medical Review', '60', '9. Safety Reporting', '60', '9.1. Definitions of Adverse Events, Serious Adverse Events, and Special', 'Situations', '60', '9.1.1. Adverse Events', '60', '9.1.2. Serious Adverse Events', '60', '9.1.3. Unlisted (Unexpected) Adverse Event/Reference Safety Information', '61', '9.1.4. Adverse Events of Special Interest', '61', '9.1.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as', 'Adverse Events or Serious Adverse Events', '61', '9.1.6. Special Situations', '61', '9.2. Assessment of Adverse Events and Serious Adverse Events', '62', '9.2.1. Assessment of Causality', '62', '9.2.2. Assessment of Severity', '63', '9.2.3. Outcome', '63', '9.3. Investigator Requirements and Instructions for Reporting Adverse Events,', 'Serious Adverse Events, Pregnancies, and Other Special Situations to the', 'Sponsor', '64', '9.3.1. Adverse Events', '64', '9.3.2. Serious Adverse Events', '64', '9.3.3. Pregnancy', '65', '9.3.4. Reporting of Special Situations (Other Than Pregnancy) and Associated', 'Adverse Events', '65', '9.4. Sponsor Reporting Requirements', '65', \"10. Sponsor's and Investigator's Responsibilities\", '66', \"10.1. Sponsor's Responsibilities\", '66', '10.1.1. Regulatory Approval/Notification', '66', '10.1.2. Clinical Study Closure Considerations', '66', '10.1.3. Indemnification', '67', '10.1.4. Insurance', '67', '10.1.5. Reporting', '67', '10.1.6. Publication', '67', \"10.2. Investigator's Responsibilities\", '68', '10.2.1. Financial Disclosure', '68', '10.2.2. Source Data and Data Capture', '68', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}